购物车
- 全部删除
- 您的购物车当前为空
NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI,主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。
为众多的药物研发团队赋能,
让新药发现更简单!
NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI,主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 455 | 现货 | |
5 mg | ¥ 1,180 | 现货 | |
10 mg | ¥ 1,880 | 现货 | |
25 mg | ¥ 3,730 | 现货 | |
50 mg | ¥ 5,320 | 现货 | |
100 mg | ¥ 7,280 | 现货 | |
200 mg | ¥ 9,790 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,280 | 现货 |
产品描述 | NT157 is a small molecule tyrphostin targeting IRS protein and has the potential to inhibit IGF-1R and STAT3 signaling pathways in TME cancer cells and stromal cells, resulting in decreased cancer cell survival. |
靶点活性 | IRS1/2:0.3 to 0.8 μM |
体外活性 | NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro[2]. |
体内活性 | NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel[2]. |
分子量 | 412.26 |
分子式 | C16H14BrNO5S |
CAS No. | 1384426-12-3 |
Smiles | C(=C/C(NCC1=CC(O)=C(O)C(O)=C1)=S)\C2=CC(Br)=C(O)C(O)=C2 |
密度 | 1.794 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 77 mg/mL (186.78 mM) Ethanol: 25.83 mg/mL (186.78 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
|
评论内容